LL-37 is a naturally occurring human peptide that has become an established subject in antimicrobial and innate immunity research. Much of that interest comes from its unusual combination of structural and biological properties.
Rather than acting through one clearly defined pathway, LL-37 has been studied for interactions with microbial membranes, bacterial surface components, biofilms and host-cell signalling systems. Researchers have also found that its behaviour can change considerably depending on the experimental environment.
That makes LL-37 an interesting model for studying how antimicrobial peptides interact with biological membranes and microbial systems. It also makes the evidence more complicated than a simple description of LL-37 as an antimicrobial compound might suggest.
This article looks at what laboratory research has established so far, where different mechanistic models agree or conflict, and what remains uncertain.
Key Areas of LL-37 Antimicrobial Research
| Research area | What researchers investigate | |
|---|---|---|
| Membrane interaction | How LL-37 associates with lipid bilayers | |
| Membrane permeability | Whether peptide exposure alters membrane integrity | |
| Peptide structure | Changes in LL-37 conformation during membrane binding | |
| Biofilm research | Effects on attachment, biofilm development and established biofilm systems | |
| Bacterial components | Interactions with molecules such as lipopolysaccharide | |
| Host-cell signalling | Cellular responses associated with LL-37 exposure | |
| Structure-activity relationships | How changes to the LL-37 sequence alter experimental behaviour |
What Is LL-37?
LL-37 is a 37-amino-acid human cathelicidin peptide studied for its interactions with microbial membranes, bacterial components and host-cell signalling systems.
LL-37 is a 37-amino-acid peptide derived from the C-terminal region of the human cathelicidin precursor protein hCAP18. It is the only identified human member of the cathelicidin family.
The peptide is cationic and is capable of forming an amphipathic alpha-helical structure; this is of particular importance in the field of antimicrobial research since microbial membranes usually have negatively charged parts which can interact with cationic peptides.
LL-37 is produced naturally by several cell types, including epithelial cells and leukocytes. Research has therefore examined it as part of the wider network of molecules associated with innate immune responses.
Its biological activity is not limited to direct interactions with microorganisms. Studies have reported interactions involving bacterial products, cellular receptors and signalling pathways. For this reason, LL-37 is also described in scientific literature as a host-defence peptide.
This broader biological context is important. Antimicrobial activity observed in an isolated laboratory system should not be treated as evidence of an equivalent effect in a whole organism.
Why Is LL-37 Studied in Antimicrobial Research?
A large part of LL-37 research concerns the way the peptide interacts with microbial membranes.
Unlike conventional antimicrobial compounds that may act on a specific enzyme or metabolic target, membrane-active peptides can interact directly with lipid bilayers. LL-37 has therefore been investigated using bacterial cultures, artificial membrane systems, spectroscopy, microscopy and other experimental approaches.
The table above highlights several connected areas explored in published LL-37 research.
LL-37 and Microbial Membranes
Electrostatic interactions
One starting point for understanding LL-37 is charge.
LL-37 carries a net positive charge under physiological conditions. Many microbial membrane surfaces contain negatively charged lipids and other anionic components. This creates the potential for electrostatic interactions between the peptide and membrane surface.
Experiments using model lipid systems have shown that membrane composition can influence how strongly LL-37 interacts with a bilayer and what happens after binding.
This means the membrane itself is part of the experimental question. Results obtained with one lipid composition cannot automatically be transferred to another.
Alpha-helical structure
LL-37 can adopt an alpha-helical conformation when associated with membranes.
Its amphipathic structure creates regions with different chemical properties. Hydrophobic residues can interact with the lipid portion of a membrane, while charged residues remain associated with the surrounding aqueous environment or charged lipid groups.
Researchers have used techniques including nuclear magnetic resonance, circular dichroism, neutron scattering and X-ray diffraction to examine these interactions.
The resulting picture is not completely uniform.
Several models have been proposed to explain LL-37-associated membrane disruption.
How Might LL-37 Alter Membrane Structure?
LL-37 may alter membrane structure through surface-associated disruption or pore formation, with the observed mechanism depending on the experimental conditions and membrane system.
Early mechanistic work suggested that LL-37 could interact with negatively charged membranes through a surface-associated or “carpet-like” process.
In this model, peptides accumulate across the membrane surface. Once sufficient peptide is present, the organisation of the lipid bilayer can be disturbed.
Other experimental work has produced evidence consistent with pore formation.
For example, structural studies have found that LL-37 can assume orientations that are compatible with transmembrane pores under certain experimental conditions, and separate research looking at lipid bilayer disruption has lent support to models which involve membrane curvature and toroidal pore formation.
These findings should not necessarily be viewed as mutually exclusive.
Membrane behaviour depends on factors including:
- lipid composition
- peptide-to-lipid ratio
- peptide concentration
- membrane charge
- hydration
- cholesterol content
- experimental model
LL-37 may therefore interact differently with different membrane systems.
The more useful conclusion is not that one universal membrane model has been proven, but that LL-37 can substantially alter membrane organisation under defined laboratory conditions.
Membrane Selectivity Is an Important Research Question
An antimicrobial peptide cannot be understood simply by establishing that it disrupts a model bacterial membrane.
Researchers also need to investigate how it behaves around other membrane types.
Experiments using synthetic lipid vesicles have found differences between negatively charged membranes and zwitterionic or cholesterol-containing systems. One study, for example, reported efficient LL-37-associated leakage from vesicles containing negatively charged POPG, while cholesterol reduced the observed leakage.
Other research has demonstrated that LL-37 can interact with eukaryotic cells under some experimental conditions.
This is one reason membrane composition and cell selectivity remain significant areas of LL-37 research. Antimicrobial activity in vitro does not, by itself, establish biological selectivity or suitability for clinical use.
LL-37 and Bacterial Biofilm Research
Planktonic bacterial cultures are only one experimental model used in antimicrobial research.
Bacteria can also grow as organised communities known as biofilms. These structures contain microbial cells within an extracellular matrix and can behave differently from free-living cells.
LL-37 has been examined in several biofilm models.
Experimental studies have reported changes involving:
- initial bacterial attachment
- biofilm formation
- biofilm biomass
- membrane integrity
- biofilm-associated signalling
- expression of genes involved in biofilm behaviour
For example, laboratory work with Staphylococcus epidermidis found that LL-37 exposure reduced bacterial attachment and biofilm mass under the conditions tested. Importantly, the researchers observed these changes at concentrations that did not inhibit planktonic bacterial growth, suggesting that biofilm-related effects could involve mechanisms beyond straightforward growth inhibition.
Research involving other bacterial species has produced additional evidence of interactions with biofilm systems.
However, biofilms differ considerably between species, laboratory models and environmental conditions. An effect observed in one biofilm assay should therefore not be treated as a universal property across microbial systems.
Interactions With Bacterial Components
LL-37 research also extends beyond intact bacterial membranes.
One area concerns lipopolysaccharide, commonly abbreviated to LPS, which is a component of the outer membrane of Gram-negative bacteria.
LL-37 is positively charged, while LPS contains negatively charged regions. Laboratory research has demonstrated interactions between these molecules.
This provides researchers with another route for examining LL-37 biology. Instead of asking only whether the peptide alters a microbial membrane, experiments can investigate how it behaves around individual bacterial components and how those interactions affect downstream experimental readouts.
Similar research has considered lipoteichoic acid associated with Gram-positive bacteria.
These mechanisms sit at the boundary between microbiology and host-response research, illustrating why LL-37 is studied across several fields rather than solely as a membrane-active peptide.
LL-37 and Cellular Signalling
LL-37 has also been investigated in mammalian cell models.
Published studies describe interactions with several receptors and signalling systems, although the mechanisms are not always straightforward. A review of LL-37-associated receptor activation noted that evidence for conventional ligand-receptor interactions is limited for some proposed targets.
Experimental research has instead produced a more complex picture involving direct and indirect receptor activation, membrane interactions and downstream signalling responses.
Reported research targets and pathways include G protein-coupled receptors, Toll-like receptors and signalling systems involving intracellular calcium.
These observations expand the scientific context of LL-37, but they also introduce another layer of uncertainty.
Cellular signalling data can depend heavily on cell type, peptide concentration and experimental design. Such findings should not be converted into claims about physiological or clinical outcomes.
What Do Structure-Activity Studies Tell Us?
Structure-activity studies show that changes to the LL-37 sequence can alter properties such as charge, membrane interactions and antimicrobial activity in experimental models.
Researchers have produced shortened fragments and modified derivatives of LL-37 to examine which parts of the sequence contribute to particular experimental effects.
This type of work is known as structure-activity relationship research.
A derivative may differ from full-length LL-37 in:
- net charge
- hydrophobicity
- alpha-helical structure
- membrane affinity
- antimicrobial activity in a specific assay
- interaction with a particular bacterial species
These comparisons can help researchers investigate which molecular characteristics contribute to membrane interaction or other measured effects.
They also demonstrate why findings from an LL-37 fragment cannot automatically be attributed to full-length LL-37. Even relatively small sequence changes can alter experimental behaviour.
What Are the Limitations of Current LL-37 Research?
LL-37 has a substantial published literature, but that does not mean every aspect of its biology is settled.
Several limitations need to be considered when interpreting the evidence.
Experimental conditions vary widely
Concentration, salt conditions, membrane makeup, type of bacteria, and test setup can all affect results.
Model membranes simplify biological systems
Although artificial lipid bilayers are useful for the study of specific molecular interactions, they fail to replicate the complete complexity of cellular membranes or of whole biological systems.
Results differ between microorganisms
Activity observed against one bacterial species or strain cannot automatically be extrapolated to another.
LL-37 has multiple biological interactions
The peptide can interact with membranes, microbial components and host-cell systems. Separating these mechanisms experimentally can be difficult.
In vitro findings have defined boundaries
The mechanistic evidence referred to in this article is obtained from experiments involving cells, microorganisms or artificial membranes. Although these models are able to demonstrate molecular interactions under controlled conditions they cannot prove clinical efficacy.
Where Does LL-37 Research Stand?
LL-37 provides a useful experimental model for investigating the relationship between peptide structure, membrane composition and antimicrobial behaviour.
Research has moved beyond the simple idea that the peptide acts through a single membrane-disruption mechanism. Current evidence instead points towards context-dependent interactions that can involve membrane binding, changes in bilayer organisation, pore formation under some experimental conditions, biofilm-associated processes and interactions with bacterial components.
That complexity is part of what makes LL-37 scientifically interesting.
It also means individual studies need to be interpreted according to the model that was actually tested. A lipid-vesicle experiment answers a different question from a bacterial biofilm assay, and neither should be presented as direct evidence of an outcome in humans.
More experimental work is still being carried out to investigate these mechanisms and the conditions that affect them.
What Does the Current LL-37 Research Show?
Research shows that LL-37 can interact with microbial membranes, bacterial components and biofilm systems under controlled experimental conditions. Its behaviour varies with the model and environment studied, so these findings help explain antimicrobial mechanisms but do not establish clinical efficacy or human outcomes.
FAQs About LL-37 Antimicrobial Research
LL-37 is studied as a human host-defence peptide with measurable interactions involving microbial membranes, bacterial surface components and biofilm systems. Researchers use it to investigate peptide-membrane behaviour, structure-activity relationships and other mechanisms relevant to innate immunity.
Laboratory studies suggest that LL-37 can bind to negatively charged membrane surfaces and alter lipid organisation. Different experimental models have produced evidence for several possible mechanisms, including surface-associated disruption and pore formation, so no single model explains every observed result.
LL-37 behaviour can be affected by peptide concentration, salt conditions, membrane composition, bacterial species and the type of assay used. Results from one experimental system therefore should not be assumed to apply directly to another.
Yes. LL-37 has been examined in several laboratory biofilm systems, including studies of bacterial attachment, biofilm development and changes in biofilm-associated behaviour. These findings are model-specific and do not establish clinical outcomes.
Antimicrobial studies usually examine interactions with microorganisms, membranes or microbial components. Host-cell research instead investigates how LL-37 may influence receptors, signalling pathways or cellular responses. These are related but distinct areas of investigation.
No. In vitro, membrane and cell-based experiments can help define molecular mechanisms under controlled conditions, but they do not establish clinical efficacy, safety or suitability for human use. Further evidence would be required before drawing conclusions beyond the experimental model.
Scientific references
- 1 Dürr UH, Sudheendra US, Ramamoorthy A. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta. 2006 Sep;1758(9):1408-25. doi: 10.1016/j.bbamem.2006.03.030. https://pubmed.ncbi.nlm.nih.gov/16716248/
- 2 Lee CC, Sun Y, Qian S, Huang HW. Transmembrane pores formed by human antimicrobial peptide LL-37. Biophys J. 2011 Apr 6;100(7):1688-96. doi: 10.1016/j.bpj.2011.02.018. https://pmc.ncbi.nlm.nih.gov/articles/PMC3072607/
- 3 Hell E, Giske CG, Nelson A, Römling U, Marchini G. Human cathelicidin peptide LL37 inhibits both attachment capability and biofilm formation of Staphylococcus epidermidis. Lett Appl Microbiol. 2010 Feb;50(2):211-5. doi: 10.1111/j.1472-765X.2009.02778.x. https://pubmed.ncbi.nlm.nih.gov/20002576/
- 4 Verjans ET, Zels S, Luyten W, Landuyt B, Schoofs L. Molecular mechanisms of LL-37-induced receptor activation: An overview. Peptides. 2016 Nov;85:16-26. doi: 10.1016/j.peptides.2016.09.002. https://pubmed.ncbi.nlm.nih.gov/27609777/
Research-use disclaimer: For research and laboratory use only. Not for human or animal consumption.